Myelodysplastic syndrome is a rapidly increasing medical concern, particularly for infants and children. It may be due to defects in the hematological potential, blood pressure, and platelet function, or by abnormalities in the lymphatic system or the immune response of the body. A diagnosis of MDS requires to be sophisticated laboratory and radiological tests. The diagnostic methods used include serum blood count, serology test, blood differential analysis, blood cell analysis, and computerized tomography scan of the breastbone area.
Myelodysplastic syndrome (MDS), also known as myelodysplasia, is an uncommon group of bone marrow diseases that affect the production of healthy blood cells (red blood cells, platelets, and white blood cells). This condition usually begins during childhood and leads to life-threatening complications such as stroke, cancer, bone marrow depression, and anemia
A myelodysplastic syndrome is a group of diseases that lead to abnormal production of the blood and bone marrow, disrupting the normal function of the organs. This condition usually begins during childhood and leads to life-threatening complications such as stroke, cancer, anemia, and bone marrow depression.
MDS typically affects infancy males or infants who lack growth in the arms, legs, and/or abdomen. Short stature, congenital abnormalities in body composition, and low birth weight are the common conditions resulting from this condition. Blood analysis results are usually normal in individuals with this disorder. However, additional tests are needed to confirm the diagnosis of myelodysplastic Syndromes.
An imbalance in the production of the red blood cells (RBC) and white blood cells (WBCs) in the bone marrow is believed to be one of the causal factors of this disorder. The myelodysplastic syndrome occurs due to a defect in the production of the RBC and WBCs. Other causes may include fetal abnormalities, infection, rejection of the fetus by the mother's uterus, genetic defects, abnormal bone marrow production, chemotherapy, radiation therapy, and adverse pregnancy experiences.
The myelodysplastic syndrome can be controlled by the use of potent drugs and combination therapy with anti-angiogenic and anti-cellular immunity agents. It can also be affected by alterations in diet and supplementation with rich, live foods and amino acids. Myelodysplastic Syndrome (MDS) Treatment is based on the type of myelodysplastic syndrome subtypes.
Risk factors include low birth weight, premature birth, congenital heart diseases, low birth length, iron-deficient anemia, and peripheral arterial malformations. Infection, smoking, drug abuse, meningitis, seroconversion disorders, and trauma are also known to increase the risk of the occurrence of the syndrome. Myelodysplastic Syndromes have a high incidence in newborns and those with severe genetic anemia. Myelodysplastic Syndromes occur most commonly in women and appear to be more common in Caucasians. Diagnosis of MDS is based on the results of laboratory tests that show the presence of anemia, chronic hemoglobinuria, leucocytosis, or evidence of lymphocytic leukemia. Treatment of anemia and other anemia-related symptoms may include vitamin D analogs and drugs such as doxycycline and rifampicin. Myelodysplastic Syndrome (MDS) Treatment includes bone marrow transplantation and chemotherapy.